Why Nordion, Inc. Shares Soared Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Nordion, Inc. popped 11% today after sterilization services provider Sterigenics agreed to acquire the Canadian medical isotopes supplier for $727 million.

So what: The all-cash deal values Nordion at $11.75 per share and represents a 13% premium to its closing price on Friday. Nordion is one of the world's biggest producers of molybdenum-99, an isotope used in medical imaging, so Sterigenics is naturally making the move to expand its presence in the growing field of gamma sterilization.

Now what: The transaction isn't subject to any financial conditions and is expected to close in the second half of this year. "This transaction delivers value to our shareholders and is a good strategic fit for Nordion", said Nordion CEO Steve West. "We believe this partnership is beneficial to Nordion's employees and our customers, as Nordion and Sterigenics combine their global expertise, industry knowledge and the same focus on high quality standards and values. This transaction also marks the successful completion of Nordion's strategic review." But while Nordion shareholders can certainly wait for the full price of $11.75, rolling at least some of today's profit into more diversified plays like Balchem and Covidien certainly seems prudent.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

The article Why Nordion, Inc. Shares Soared Today originally appeared on Fool.com.

Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.